Relmada Therapeutics (NASDAQ: RLMD) reported Q3 EPS of ($2.44), $0.84 worse than the analyst estimate of ($1.60).

As of September 30, 2021, the Company had cash and short-term investments of $88.1 million, compared to cash, cash equivalents, and short-term investments of approximately $117.1 million at December 31, 2021.

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.